Prolonged Shedding of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at High Viral Loads Among Hospitalized Immunocompromised Persons Living With Human Immunodeficiency Virus (HIV), South Africa

Susan Meiring, Stefano Tempia, Jinal N. Bhiman, Amelia Buys, Jackie Kleynhans, Mvuyo Makhasi, Meredith McMorrow, Jocelyn Moyes, Vanessa Quan, Sibongile Walaza, Mignon du Plessis, Nicole Wolter, Anne von Gottberg, and Cheryl Cohen; the COVID-19 shedding study group

Division of Public Health Surveillance and Response, National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Johannesburg, South Africa; Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, a Division of the National Health Laboratory Service, Johannesburg, South Africa; Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; Division of Viral Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia, USA; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; and School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

Background. We assessed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA shedding duration and magnitude among persons living with human immunodeficiency virus (HIV, PLHIV).

Methods. From May through December 2020, we conducted a prospective cohort study at 20 hospitals in South Africa. Adults hospitalized with symptomatic coronavirus disease 2019 (COVID-19) were enrolled and followed every 2 days with nasopharyngeal/oropharyngeal (NP/OP) swabs until documentation of cessation of SARS-CoV-2 shedding (2 consecutive negative NP/OP swabs). Real-time reverse transcription-polymerase chain reaction testing for SARS-CoV-2 was performed, and cycle-threshold (Ct) values < 30 were considered a proxy for high SARS-CoV-2 viral load. Factors associated with prolonged shedding were assessed using accelerated time-failure Weibull regression models.

Results. Of 2175 COVID-19 patients screened, 300 were enrolled, and 257 individuals (155 HIV-uninfected and 102 PLHIV) had > 1 swabbing visit (median 5 visits [range 2–21]). Median time to cessation of shedding was 13 days (interquartile range [IQR] 6–25) and did not differ significantly by HIV infection. Among a subset of 94 patients (41 PLHIV and 53 HIV-uninfected) with initial respiratory sample C_{t} value < 30, median time of shedding at high SARS-CoV-2 viral load was 8 days (IQR 4–17). This was significantly longer in PLHIV with CD4 count < 200 cells/µL, compared to HIV-uninfected persons (median 27 days [IQR 8–43] vs 7 days [IQR 4–13]; adjusted hazard ratio [aHR] 0.14, 95% confidence interval [CI] 0.07–0.28, P < .001), as well as in unsuppressed-HIV versus HIV-uninfected persons.

Conclusions. Although SARS-CoV-2 shedding duration did not differ significantly by HIV infection, among a subset with high initial SARS-CoV-2 viral loads, immunocompromised PLHIV shed SARS-CoV-2 at high viral loads for longer than HIV-uninfected persons. Better HIV control may potentially decrease transmission time of SARS-CoV-2.

Keywords. COVID-19; HIV; immunocompromised; respiratory virus; shedding duration.

Immunocompromised persons are thought to shed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for a longer duration, increasing time for viral transmission and potentially driving within host viral evolution [1–3]. South Africa has 7 500 000 persons living with human immunodeficiency virus (HIV, PLHIV), and there are no systematically collected data on duration of SARS-CoV-2 shedding in PLHIV. We hypothesized that PLHIV may shed SARS-CoV-2 for a longer period of time and at a higher viral load than HIV-uninfected individuals.

SARS-CoV-2 shedding from the upper respiratory tract extends for a mean of 17 days (15.5–18.6) [4]. Unlike severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1), viral shedding of SARS-CoV-2 from the upper respiratory tract peaks on or before symptom onset, allowing some viral transmission to occur before symptom onset in infected individuals [4–8]. Quantifying SARS-CoV-2 viral load (Log_{10} RNA copies/mL) is calculated by converting qualitative real-time reverse transcription-polymerase chain reaction (rRT-PCR) cycle threshold values using calibration curves based on quantified E-gene in vitro RNA transcripts [9]. However, studies...
on SARS-CoV-2 infectiousness indicate that successful virus isolation is most likely from specimens with a rRT-PCR cycle threshold (Ct) value < 34 (~7 Log10 copies/mL); however, not all of these specimens may be positive for viable virus [9, 10]. Using this threshold, infectiousness declines significantly 8 days after becoming symptomatic, even though SARS-CoV-2 viral RNA persistence has been shown to occur for months in some individuals [9, 11, 12].

Various factors have been associated with increased shedding duration, including increased age, male sex, severity of illness and use of corticosteroids [13, 14]. There are several published case reports indicating prolonged SARS-CoV-2 transmission in immunocompromised persons, mostly with cancers or auto-immune conditions, and more recently in an immunocompromised person living with HIV [15–18].

We aimed to evaluate the overall duration of SARS-CoV-2 shedding in upper respiratory tract specimens and duration of high viral load shedding in a cohort of PLHIV and HIV-uninfected persons hospitalized with COVID-19 in South Africa. We also estimated SARS-CoV-2 shedding duration in stool and blood specimens, and described serologic responses to SARS-CoV-2 infection.

**METHODS**

**Study Design and Setting**

We conducted a prospective cohort study from 1 May through 31 December 2020 (spanning the first wave and beginning of the second wave of the COVID-19 pandemic in South Africa). Persons hospitalized for symptomatic COVID-19 at one of 20 hospitals situated in 8 of the 9 South African provinces were invited to participate in the study if they met the following inclusion criteria: aged 18 years and older, laboratory confirmed diagnosis of SARS-CoV-2 in the previous 5 days, resided within a 50-kilometer radius of the hospital, and had laboratory confirmation of their HIV status.

Using standardized case report forms, demographic and clinical details were collected at enrollment, daily while in hospital, and at discharge from hospital/cessation of shedding/death of the participant. Included variables are detailed in Supplementary Material.

At enrollment and every second day thereafter, until cessation of shedding or death, a combined nasopharyngeal/oropharyngeal (NP/OP) swab was collected by trained nursing staff, using 2 flocked nylon plastic shaft swabs (1 for the nasopharynx and 1 for the oropharynx), which were then inserted together into Universal Transport Medium and transported on ice to the laboratory. Sensitivity of the combined NP/OP swab has been shown to be 97% for detection of SARS-CoV-2 in the upper airways [19, 20]. A rectal swab or stool was collected from patients at the same time intervals and transported to the laboratory in sealed containers. Results are available in Supplementary Material. Patients were followed up at home if they were still SARS-CoV-2 positive on NP/OP swab on discharge from hospital.

Whole blood and serum specimens were taken on enrollment and at days 7, 14, and 21 post symptom-onset for SARS-CoV-2 testing and serology. Results for SARS-CoV-2 testing of blood samples are available in Supplementary Materials. All specimens were transported to the National Institute for Communicable Diseases (NICD) in Johannesburg for processing and testing.

**Laboratory Diagnostics**

rRT-PCR for the qualitative detection of nucleic acid from SARS-CoV-2 was performed on NP/OP, stool/rectal swabs and blood specimens using the Allplex™ nCoV 2019 kit (Seegene, Seoul, South Korea). Specimens were considered positive for SARS-CoV-2 nucleic acids if the Ct was < 40 for ≥ 1 of 3 gene targets. A nucleocapsid gene (N gene) Ct value < 30 on NP/OP specimens was used as a proxy for a high viral load based on published data showing a high correlation between low Ct values (using various gene targets), high viral load and increased odds of shedding cultivable virus [10, 12, 21, 22].

Antibody detection against trimeric ectodomain HexaPro spike protein was performed on serum specimens as described previously [23, 24]. Absorbance at 450 nm was measured, and specimens with optical density (OD) > 0.4 were considered positive for anti-spike protein antibodies.

SARS-CoV-2 sequencing was performed on the first NP/OP specimens on enrollment from 10 randomly selected participants of 29, who demonstrated high viral load shedding for > 14 days. Clade and lineage assignments were made using the online Nextclade (https://clades.nextstrain.org/) and Pangolin (https://pangolin.cog-uk.io/) applications, which also enable identification of known variants of concern as well as novel mutations. See Supplementary Methods for more details.

**Definitions**

Shedding was defined as presence of SARS-CoV-2 nucleic acid in a specimen as detected by a positive SARS-CoV-2 rRT-PCR result. Participants were deemed to have stopped shedding SARS-CoV-2 from the respiratory tract once 2 consecutive NP/OP swabs, taken at least 2 days apart, tested negative for all 3 gene targets on rRT-PCR. Time to cessation of shedding was taken from date of symptom onset to the date of the last rRT-PCR SARS-CoV-2 positive NP/OP swab prior to the two consecutive negative swabs. Participants were defined to be shedding SARS-CoV-2 virus at high viral loads if their NP/OP swab N gene Ct value was < 30. Persistence of high viral load was measured in the subgroup of individuals whose first study NP/OP swab had an N gene Ct value < 30 and was measured from date of symptom onset to the last date where NP/OP swab N gene Ct value was < 30. PLHIV were deemed to be
significantly immunocompromised if their CD4 T-lymphocyte count was < 200 cells/μL and not HIV virally suppressed if their HIV viral load measured > 400 copies/mL in the 3 months before hospital admission [25, 26]. Severity of COVID-19 was categorized using respiratory rate at time of admission according to the WHO clinical classification of COVID-19 and a quick Sequential (Sepsis-related) Organ Failure Assessment (qSOFA) score [27, 28].

Statistical Analysis
Data were captured on a real-time data capture (REDCAP) database and transferred onto a password protected Microsoft Access database management system [29]. Statistical analysis was performed using Stata version 14 (StataCorp Inc., College Station, Texas, USA).

We used Kaplan-Meier estimates and Weibull accelerated failure time regression models to measure time from symptom onset to (i) cessation of shedding and (ii) low viral load shedding (at Ct values > 30). The Weibull model was chosen as it allows explanatory variables to proportionately increase or decrease the time to the end-point [30]. Hazard ratios measured the hazard of reaching the end-points with a ratio of < 1 indicating a longer duration of shedding or a longer duration of high viral load shedding. P-values < .2 on univariate analysis were included in all multivariable models, and nonsignificant variables (P-value > .05) were dropped using step-wise manual backward elimination. Patients with missing data were dropped from the models.

Ethics
Ethics clearance for the study was obtained through various university health research ethics committees (HREC), namely, University of the Witwatersrand HREC (Medical) (M160667); Stellenbosch University HREC (15206); University of Pretoria HREC (256/2020), and University of the Free State HREC (HSD2020/0625). Permission to conduct the study was obtained from each Provincial Department of Health Research Committee. All participants gave written informed consent to participate in the study.

RESULTS

Participant Inclusion and Characterization
From 1 May through 31 December 2020, 2175 hospitalized COVID-19 patients were screened for enrolment at 20 sentinel hospitals across South Africa (Figure 1). Of the 1875 not enrolled: 225 refused consent, 186 were transferred out of the hospital on the day of screening, 64 were minors, and 1400 did not meet the eligibility criteria (Figure 1 and Supplementary Table 1). Three hundred persons were enrolled into the study of which 257 had at least 2 study visits (range 2–21), with a median of 5 visits per participant (Supplementary Figure 1). Of these, 155 persons were HIV-uninfected and 102 PLHIV (Figure 1).

Of the 257 patients included in the cohort: median age was 46 years (IQR 35–58 years), PLHIV were significantly younger than HIV-uninfected persons (median of 41 years in PLHIV and 49 years in HIV-uninfected, P < .001). Sixty-one percent of participants were female with significantly more females than males represented among PLHIV (P < .001). The majority of participants (86%) were of Black African descent. Overall, 33% had underlying hypertension (40% HIV-uninfected vs 24% PLHIV, P = .01), 21% had diabetes (28% HIV-uninfected vs 11% PLHIV, P = .002), 16% were obese (19% HIV-uninfected vs 13% PLHIV, P = .25), and 8% had underlying tuberculosis (2% HIV-uninfected vs 16% PLHIV, P < .001). Thirteen percent were current cigarette smokers (Table 1). Of PLHIV, 84% were currently receiving antiretroviral therapy, median CD4 T-cell count was 221 cells/μL (IQR 48–443) (with 53% having CD4 T-cell count > 200 cells/μL), and 59% were HIV virally suppressed (HIV viral load < 400 copies/mL).

Patients were admitted for a median of 9 days (IQR 6–13) in hospital. Eight participants had unknown outcome. Overall, 10% (24/250) of participants died, 8% (19) during their hospital admission, and a further 2% (5) within 2 months post-discharge. This did not differ significantly by HIV status. Of 214 participants with known parameters to assess disease severity, most (64%, 137/214) had moderate disease severity, with 18% (39/214) having mild and 18% (38/214) having severe COVID-19. HIV-uninfected persons and PLHIV had similar clinical presentation. The most common presenting symptoms were cough (79%, 192/243), dyspnea (66%, 160/243), chest pain (63%, 153/243), malaise (52%, 127/243), and fever (45%, 111/243). Oxygen therapy was required for 53% (125/235), noninvasive ventilation for 7% (15/227), and invasive ventilation for 5% (11/230). Ten percent (23/235) were admitted to an intensive care unit. Glucocorticoids were given to 34% (84/250) of individuals while in hospital (Table 1).

Factors Associated With Duration of Shedding
Of the 257 participants with at least 2 swabbing visits: 186 were followed up until cessation of SARS-CoV-2 shedding, 14 died prior to stopping shedding, and 57 were lost to follow-up. Overall, there were 4881 patient days of observation. The median duration of SARS-CoV-2 shedding from the 257 participants was 13 days (IQR 6–25) from symptom onset: 15 days (IQR 8–27) in HIV-uninfected versus 11 days (IQR 5–22) in PLHIV (adjusted hazard ratio [aHR]) 1.16, 95% confidence interval [CI] .8–1.68, P = .44). Duration of SARS-CoV-2 shedding was not significantly different by different age categories, sex, HIV immunosuppression, severity of illness, and use of glucocorticoids. However, after adjusting for confounders on multivariable analysis, the duration of SARS-CoV-2 detection
was 45% longer in obese compared to non-obese persons (18 days [IQR 11–34] vs 13 days (IQR 6–25), aHR 0.55, 95% CI .33–.90, \( P = .02 \)) (Table 2; Figure 2; Supplementary Table 2).

Factors Associated With Shedding Potentially Infectious Virus
Of a subset of 94 participants with N gene Ct value < 30 at enrolment (41 PLHIV and 53 HIV-uninfected persons), the median duration of SARS-CoV-2 shedding at N gene Ct value < 30 from symptom onset was 8 days (IQR 4–17). On multivariable analysis, when adjusting for age and glucocorticoid use, PLHIV with a CD4 cell count < 200 cells/µL shed at high SARS-CoV-2 viral loads for longer (median 27 days, IQR 8–43, aHR 0.14, 95% CI .07–.28, \( P < .001 \)), whereas PLHIV with CD4 count > 200 cells/µL shed at high SARS-CoV-2 viral loads for a similar time period (median 7 days, IQR 4–10, aHR 1.14, 95% CI .56–2.31, \( P = .71 \)), compared to HIV-uninfected persons (median 7 days, IQR 4–13). Similarly, PLHIV with HIV viral loads > 400 copies/mL were more likely to shed SARS-CoV-2 at high viral loads for longer (26 days, IQR 10–41, unadjusted HR 0.34, 95% CI .18–.64, \( P < .001 \)) than PLHIV with HIV viral suppression (6 days, IQR 4–8, unadjusted HR 1.77, 95% CI .88–3.56, \( P = .107 \)) and those who were HIV-uninfected (7 days, IQR 4–13) (Table 3; Figure 3; Supplementary Table 3).

SARS-CoV-2 Antibodies
The proportion of participants with positive anti-spike protein antibodies increased from 80% (161/201) by day 7 to 87% (135/156) at day 14 post-symptom onset. PLHIV with CD4 count < 200 cells/µL were significantly less likely to develop anti-spike protein antibody titers by day 7, 14, or 21 post-symptom-onset than HIV-uninfected persons (Table 4). Median anti-spike protein antibody titers were significantly higher by 7 and 14 days post-symptom onset in HIV-uninfected persons (Figure 4). By day 21, there were 4 HIV-uninfected and 10 PLHIV (8 with CD4 counts < 200 cells/µL, 1 with CD4 count > 200 cells/µL and 1 with unknown CD4 count) who did not develop anti-spike protein antibodies. Seven (2 HIV-uninfected and 5 PLHIV with CD4
| Characteristics on admission | All | HIV-uninfected | Persons Living With HIV | P value |
|------------------------------|-----|---------------|-------------------------|---------|
| Age in years (median and IQR) | 46 | 35–58 | 49 | 37–64 | 41 | 34–52 | <.001 |
| Age category (n = 253) | | | | | | | |
| 18–34 years | 61 | 24 | 33 | 22 | 28 | 28 | <.001 |
| 35–59 years | 135 | 53 | 72 | 47 | 63 | 62 | | |
| ≥60 years | 57 | 23 | 47 | 31 | 10 | 10 | | |
| Sex (n = 254) | | | | | | | |
| Female | 155 | 61 | 77 | 51 | 78 | 76 | <.001 |
| Male | 99 | 39 | 75 | 49 | 24 | 24 | | |
| Race (n = 233) | | | | | | | |
| Black African | 201 | 86 | 103 | 77 | 98 | 98 | <.001 |
| Mixed race | 20 | 9 | 18 | 14 | 2 | 2 | | |
| Asian/Indian | 11 | 5 | 11 | 8 | 0 | 0 | | |
| Other | 1 | 0 | 1 | 1 | 0 | 0 | | |
| Comorbidities | | | | | | | |
| Chronic cardiac conditions (n = 232) | 14 | 6 | 8 | 6 | 6 | 6 | .989 |
| Hypertension (n = 232) | 77 | 33 | 53 | 40 | 24 | 24 | .013 |
| Diabetes (n = 232) | 48 | 21 | 37 | 28 | 11 | 11 | .002 |
| Chronic kidney disease (n = 230) | 5 | 2 | 4 | 3 | 1 | 1 | .293 |
| Obesity (n = 232) | 38 | 16 | 25 | 19 | 16 | 16 | | |
| Current tuberculosis (n = 231) | 18 | 8 | 2 | 2 | 16 | 16 | | |
| Smoking history (n = 166) | | | | | | | |
| Current smoker | 21 | 13 | 12 | 13 | 9 | 12 | .805 |
| Former smoker | 17 | 10 | 8 | 9 | 9 | 12 | | |
| Nonsmoker | 128 | 77 | 70 | 78 | 58 | 76 | | |
| Days from symptom onset to admission (median and IQR) | 3 | 1–5 | 3 | 1–5 | 2 | 1–6 | .281 |
| Disease severity on admission (WHO severity of COVID-19, qSOFA score) (n = 214) | 121 | 93 | | | | | |
| Mild | 39 | 18 | 20 | 17 | 19 | 20 | .401 |
| Moderate | 137 | 64 | 76 | 63 | 61 | 66 | | |
| Severe | 38 | 18 | 25 | 21 | 13 | 14 | | |
| Signs and symptoms (n = 243) | | | | | | | |
| Fever | 111 | 45 | 68 | 48 | 43 | 43 | .483 |
| Cough | 192 | 79 | 113 | 79 | 79 | 79 | .849 |
| Dry | 115 | 60 | 73 | 65 | 42 | 53 | .234 |
| Productive | 59 | 31 | 30 | 27 | 29 | 37 | | |
| Hemoptysis | 18 | 9 | 10 | 9 | 8 | 10 | | |
| Sore throat | 79 | 33 | 50 | 35 | 29 | 29 | .329 |
| Chest pain | 153 | 63 | 94 | 66 | 59 | 59 | .285 |
| Myalgia | 77 | 32 | 47 | 33 | 30 | 30 | .636 |
| Malaise | 127 | 52 | 76 | 53 | 51 | 51 | .742 |
| Dyspnoea | 160 | 66 | 95 | 66 | 65 | 65 | .817 |
| Confusion | 13 | 5 | 7 | 5 | 6 | 6 | .706 |
| Headache | 66 | 27 | 38 | 27 | 28 | 28 | .806 |
| Diarrhea | 49 | 20 | 25 | 17 | 24 | 24 | .213 |
| Characteristics during hospital admission | | | | | | | |
| Days in hospital (median and IQR) | 9 | 6–13 | 8 | 5–13 | 9 | 6–16 | .118 |
| Oxygen therapy required (n = 235) | 125 | 53 | 73 | 50 | 52 | 58 | .359 |
| Invasive ventilation required (n = 230) | 11 | 5 | 6 | 4 | 5 | 6 | .571 |
| Noninvasive ventilation required (n = 227) | 15 | 7 | 11 | 8 | 4 | 5 | .372 |
| ICU admission (n = 235) | 23 | 10 | 11 | 8 | 12 | 13 | .137 |
| Glucocorticoids use (250) | 84 | 34 | 51 | 34 | 33 | 34 | .616 |
| In-hospital outcome (n = 249) | | | | | | | |
| Discharged | 211 | 85 | 126 | 83 | 85 | 87 | .475 |
| Transferred | 19 | 8 | 14 | 9 | 5 | 5 | | |
| Died | 19 | 8 | 11 | 7 | 8 | 8 | | |

Abbreviations: COVID-19, coronavirus disease 2019; HIV, human immunodeficiency virus; ICU, intensive care unit; IQR, interquartile range; qSOFA, quick Sequential (Sepsis-related) Organ Failure Assessment; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; WHO, World Health Organization.
Table 2. Accelerated Weibull Regression for Duration of SARS-CoV-2 N Gene Detection by RT-PCR Among Hospitalized Patients, South Africa

| Characteristic                                                                 | Number Included in Each Category | Duration of Shedding in days, Median (IQR) | Univariate Analysis | Multivariable Analysis |
|--------------------------------------------------------------------------------|----------------------------------|------------------------------------------|---------------------|------------------------|
|                                                                                |                                  | HR            | 95% CI     | P value    | Adjusted HR | 95% CI     | P value    |
| Overall                                                                       | 13 (6–25)                        |               |            |            |            |            |            |
| Age category (years) (n = 253)                                                |                                  |               |            |            |            |            |            |
| 18–34 years                                                                   | 61                               | 0.86          | .60–1.23   | .417       | 1.01        | .65–1.56   | .973       |
| 35–59 years                                                                   | 135                              | 0.91          | .59–1.42   | .691       | 1.07        | .62–1.84   | .815       |
| ≥60 years                                                                      | 57                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Sex (n = 254)                                                                 |                                  |               |            |            |            |            |            |
| Male                                                                          | 99                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Female                                                                        | 155                              | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| HIV status (n = 257)                                                          |                                  |               |            |            |            |            |            |
| HIV-uninfected                                                                | 155                              | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| PLHIV                                                                          | 155                              | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| PLHIV CD4 ≥200                                                                 | 41                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| PLHIV CD4 < 200                                                                | 38                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| HIV viral load category (n = 257)                                             |                                  |               |            |            |            |            |            |
| HIV-uninfected                                                                | 155                              | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| PLHIV viral load < 400 copies/mL                                               | 37                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| PLHIV viral load ≥ 400 copies/mL                                               | 27                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| HIV-infected viral load unknown                                                | 38                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Glucocorticoid use (n = 247)                                                  |                                  |               |            |            |            |            |            |
| Yes                                                                           | 84                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| No                                                                            | 163                              | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Severity of illness (n = 214)                                                 |                                  |               |            |            |            |            |            |
| Mild                                                                          | 39                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Moderate                                                                      | 137                              | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Severe                                                                        | 38                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Specific comorbidities                                                        |                                  |               |            |            |            |            |            |
| Hypertension (n = 232)                                                        | 77                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| no hypertension                                                               | 155                              | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Diabetes (n = 232)                                                            | 48                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Obesity (n = 232)                                                             | 184                              | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Tuberculosis (231)                                                            | 18                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Smoking history (n = 166)                                                     |                                  |               |            |            |            |            |            |
| Current smoker                                                                | 21                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Former smoker                                                                 | 17                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| SARS-CoV-2 PCR positive on stool samples by day 7 post symptom onset (n = 200) |                                  |               |            |            |            |            |            |
| No                                                                            | 132                              | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Yes                                                                           | 68                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| SARS-CoV-2 PCR positive on stool samples at day 14 post symptom onset (n = 156) |                                  |               |            |            |            |            |            |
| No                                                                            | 113                              | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Yes                                                                           | 43                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Anti-spike protein antibodies by day 7 post symptom onset (n = 201)            |                                  |               |            |            |            |            |            |
| No                                                                            | 40                               | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
| Yes                                                                           | 161                              | 1.08          | .79–1.48   | .622       | 1.01        | .69–1.49   | .945       |
count < 200 cells/µL) of these 14 shed SARS-CoV-2 viral RNA from the upper respiratory tract for 20 days or longer post symptom-onset (all 5 PLHIV still had N gene Ct values < 26 by day 20).

**SARS-CoV-2 Sequencing of Upper Respiratory Specimens on Enrollment**

Eight different SARS-CoV-2 phylogenetic lineages were detected from enrollment NP/OP swabs from the 10 randomly selected participants demonstrating high SARS-CoV-2 viral load shedding for > 2 weeks. These included 2 participants with B.1, 2 B.1.140, and 1 each of B.1.1.57, B.1.1.448, B.1.1.382, C.1, C.2, and C.6 lineages.

**DISCUSSION**

In this South African cohort of 257 persons (including 102 PLHIV) hospitalized with COVID-19, the median duration of SARS-CoV-2 shedding was 13 days and did not differ significantly by HIV status. Among a subset with high initial SARS-CoV-2 viral shedding, duration of high viral load SARS-CoV-2 shedding (at N gene Ct value < 30) was 8 days overall and significantly prolonged in PLHIV with HIV immunosuppression and/or high HIV viral load. SARS-CoV-2 nucleic acids were detected in blood and stool/rectal swab specimens at low RNA concentrations in both PLHIV and HIV-uninfected persons. Immunocompromised PLHIV were also less likely to develop

| Characteristic | Number Included in Each Category | Survival Analysis | Duration of Shedding in days, Median (IQR) | Univariate Analysis | Multivariable Analysis |
|---------------|---------------------------------|------------------|------------------------------------------|--------------------|------------------------|
|               |                                 | Survival Analysis | Median (IQR)                               | HR 95% CI  P value | Adjusted HR 95% CI  P value |
| Anti-spike protein antibodies at day 14 post symptom onset (n = 156) | | | | | |
| No            | 21                              | 12 (3–37)        | Reference                                 |                    |                        |
| Yes           | 135                             | 15 (8–25)        | 1.32                                     | .75–2.33 .330      |                        |
| Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; IQR, interquartile range; RT-PCR, reverse transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

*CD4 – CD4 T-lymphocyte count in cells/µL.

**Figure 2.** Kaplan-Meier plots of proportion of SARS-CoV-2 shedding by days following symptom onset by (A) HIV status, (B) presence of obesity (BMI > 30), (C) HIV viral load among PLHIV, and (D) CD4 T-lymphocyte count among persons living with HIV (PLHIV). Abbreviations: BMI, body mass index; HIV, human immunodeficiency virus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Table 3. Accelerated Weibull Regression for Time Taken From Onset of Symptoms to SARS-CoV-2 RT-PCR N Gene Ct Value of ≥30 Among a Subset of Hospitalized Patients With Laboratory Confirmed SARS-CoV-2 and Initial Study SARS-CoV-2 RT-PCR N Gene Ct value < 30, South Africa (n = 94)

| Characteristic                                           | Number Included in Each Category | Median Time From Symptom Onset to SARS-CoV-2 N gene Ct value ≥30 (IQR) | Univariate Analysis | Multivariable Analysis |
|----------------------------------------------------------|----------------------------------|---------------------------------------------------------------------------|--------------------|------------------------|
|                                                          |                                  |                                                                           | HR                 | 95% CI                 | P value | HR                 | 95% CI                 | P value |
| Overall                                                  | 8 (4–17)                         |                                                                           |                    |                        |         |                    |                        |         |
| Age category (years) (n = 93)                            |                                  |                                                                           |                    |                        |         |                    |                        |         |
| 18–34 years                                              | 22                               | 7 (3–22)                                                                  | Reference          |                        |         | 1.60 .88–2.91      | .126           |         |
| 35–59 years                                              | 48                               | 8 (4–15)                                                                  | 1.51 0.86–2.63     | .150                   |         | 1.61 .3–1.25        | .175           |         |
| ≥60 years                                                | 23                               | 10 (6–16)                                                                 | 1.51 0.8–2.83      | .201                   |         |                    |                        |         |
| Sex (n = 94)                                             |                                  |                                                                           |                    |                        |         |                    |                        |         |
| Male                                                     | 42                               | 6 (4–13)                                                                  | 1.42 0.91–2.20     | .120                   |         |                    |                        |         |
| Female                                                   | 52                               | 9 (5–21)                                                                  | Reference          |                        |         |                    |                        |         |
| Immunocompromised category                               |                                  |                                                                           |                    |                        |         |                    |                        |         |
| HIV-uninfected                                           | 53                               | 7 (4–13)                                                                  | Reference          |                        |         |                    |                        |         |
| HIV-infected CD4^a ≥200                                  | 14                               | 7 (4–10)                                                                  | 1.44 .77–2.68      | .248                   |         | 1.14 .56–2.31      | .713           |         |
| HIV-infected CD4^a < 200                                 | 18                               | 27 (8–43)                                                                 | 0.23 .13–43        | <.001                  |         | 0.14 .07–28        | <.001         |         |
| HIV-infected CD4^a unknown                               | 9                                | 8 (1–19)                                                                  | 0.59 .26–1.30      | .188                   |         | 0.71 .3–1.7        | .441           |         |
| HIV viral load category                                  |                                  |                                                                           |                    |                        |         |                    |                        |         |
| HIV-uninfected                                           | 53                               | 7 (4–13)                                                                  | Reference          |                        |         |                    |                        |         |
| HIV-infected viral load < 400 copies/mL                  | 11                               | 6 (4–8)                                                                   | 1.77 .88–3.56      | .107                   |         |                    |                        |         |
| HIV-infected viral load ≥400 copies/mL                   | 13                               | 26 (10–41)                                                                | 0.34 .18–64        | .001                   |         |                    |                        |         |
| HIV-infected viral load unknown                          | 17                               | 13 (4–26)                                                                 | 0.30 .15–57        | <.001                  |         |                    |                        |         |
| Glucocorticoid use (89)                                  |                                  |                                                                           |                    |                        |         |                    |                        |         |
| Yes                                                      | 32                               | 12 (6–24)                                                                 | 0.92 .59–1.44      | .718                   |         | 1.20 .71–2.04      | .490           |         |
| No                                                       | 57                               | 7 (4–13)                                                                  | Reference          |                        |         |                    |                        |         |
| Severity of illness (n = 75)                             |                                  |                                                                           |                    |                        |         |                    |                        |         |
| Mild                                                     | 13                               | 13 (8–23)                                                                 | Reference          |                        |         |                    |                        |         |
| Moderate                                                 | 48                               | 7 (4–15)                                                                  | 1.60 .82–3.10      | .165                   |         |                    |                        |         |
| Severe                                                   | 14                               | 9 (5–37)                                                                  | 1.17 .53–2.62      | .694                   |         |                    |                        |         |
| Specific comorbidities (n = 84)                          |                                  |                                                                           |                    |                        |         |                    |                        |         |
| Hypertension                                             | 25                               | 8 (6–16)                                                                  | 1.42 .87–2.31      | .184                   |         |                    |                        |         |
| No hypertension                                          | 59                               | 9 (5–19)                                                                  | Reference          |                        |         |                    |                        |         |
| Diabetes                                                 | 16                               | 6 (3–13)                                                                  | 0.96 .52–1.77      | .888                   |         |                    |                        |         |
| No diabetes                                              | 68                               | 9 (5–19)                                                                  | Reference          |                        |         |                    |                        |         |
| Tuberculosis                                             | 9                                | 20 (8–37)                                                                 | 0.67 .34–1.35      | .268                   |         |                    |                        |         |
| No tuberculosis                                          | 75                               | 8 (5–16)                                                                  | Reference          |                        |         |                    |                        |         |
| Obesity                                                  | 16                               | 7 (4–20)                                                                  | 1.07 .60–1.92      | .809                   |         |                    |                        |         |
| No obesity                                               | 68                               | 9 (5–17)                                                                  | Reference          |                        |         |                    |                        |         |
| Smoking history (n = 62)                                 |                                  |                                                                           |                    |                        |         |                    |                        |         |
| Current smoker                                           | 7                                | 13 (11–29)                                                                | Reference          |                        |         |                    |                        |         |
| Former smoker                                            | 7                                | 11 (6–24)                                                                 | 0.87 .29–2.58      | .798                   |         |                    |                        |         |
| Nonsmoker                                                | 48                               | 8 (5–17)                                                                  | 0.99 .42–2.32      | .976                   |         |                    |                        |         |
| Spike ODB > 0.4 by day 7 post symptom onset (n = 76)      |                                  |                                                                           |                    |                        |         |                    |                        |         |
| No                                                       | 21                               | 10 (6–20)                                                                 | Reference          |                        |         |                    |                        |         |
| Yes                                                      | 55                               | 6 (4–11)                                                                  | 2.10 1.19–3.66     | .010                   |         |                    |                        |         |
| Spike ODB > 0.4 at day 14 post symptom onset (n = 56)     |                                  |                                                                           |                    |                        |         |                    |                        |         |
| No                                                       | 9                                | 37 (20–62)                                                                | Reference          |                        |         |                    |                        |         |
| Yes                                                      | 47                               | 7 (4–14)                                                                  | 6.64 2.86–15.39    | <.001                  |         |                    |                        |         |

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HR, hazard ratio; RT-PCR, reverse transcription polymerase chain reaction; IQR, interquartile range; SARS-CoV-2; severe acute respiratory syndrome coronavirus 2.

*CD4 – CD4+ lymphocyte count in cells/µL.
anti-spike protein antibody by day 7 or 14 compared to HIV-uninfected persons. A wide variety of SARS-CoV-2 phylogenetic lineages were detected in the small group of participants who shed SARS-CoV-2 at high viral loads for more than 2 weeks.

We showed prolonged duration of high viral load SARS-CoV-2 shedding in PLHIV with low CD4 cell counts. Prolonged influenza virus shedding has been described in immunocompromised PLHIV, and it has been associated with viral evolution and antigenic drift within individual immunocompromised patients, similar to that occurring in communities [31–34]. Further studies are needed to explore SARS-CoV-2 intra-individual adaptations in a similar manner to influenza, particularly in PLHIV.

The national prevalence of HIV infection in South Africa is 13%, and it is estimated that 4.4 million of the 7.5 million PLHIV in South Africa are not HIV virally suppressed. If immunocompromised PLHIV shed SARS-CoV-2 for longer at higher SARS-CoV-2 viral loads, this could potentially impact the risk of viral evolution and transmission, especially in South Africa. Alternately, PLHIV with CD4 counts of ≥200 cells/µL shed for a similar time and at a similar SARS-CoV-2 viral load than HIV-uninfected persons. This finding highlights the importance of early HIV diagnosis and treatment with the goal of HIV viral suppression, thus improving the health of PLHIV and minimizing transmission risk of SARS-CoV-2 in the general population. The study was conducted prior to any COVID-19 vaccinations being available in South Africa. Now that vaccines are available, prioritizing COVID-19 vaccination of PLHIV may be another strategy for minimizing SARS-CoV-2 spread.

Recently, accelerated SARS-CoV-2 viral evolution was described in an immunocompromised host with persistent SARS-CoV-2 infection, as well as in a PLHIV host with poor HIV viral suppression [17, 35]. SARS-CoV-2 viral mutations occur commonly within hosts and within populations and prolonged high viral load shedding provides a good opportunity for virus evolution and transmission of potential viral mutations. Between June and October 2020, 44 different SARS-CoV-2 lineages were detected in South Africa, with the B.1, B.1.1.448, B.1.1.54, and C.1 lineages accounting for 59% of all sequences (n = 1705) [36]. In this study the multiple SARS-CoV-2 phylogenetic lineages detected reflect the lineage diversity during the earlier waves in South Africa, indicating that persistent shedding was not dominated by a specific lineage or variant. All lineages detected in these individuals had been identified in national genomic surveillance efforts, with 7 of the 8 being lineages first detected in South Africa [36]. Going forward we aim to investigate within host viral evolution by sequencing sequential specimens of the participants with prolonged high viral load shedding, many of whom were immunocompromised PLHIV.

| Table 4. SARS-CoV-2 Serology Results by HIV-status at Day 7, 14, and 21 Post Symptom Onset, Among Hospitalized Persons with Laboratory Confirmed SARS-CoV-2, South Africa (n = 201) |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| **Number with anti-spike protein antibodies** | **Number with anti-spike protein antibodies** | **Number with anti-spike protein antibodies** |
| **n/N (%)** | **n/N (%)** | **n/N (%)** |
| **P-value** | **P-value** | **P-value** |
| **n/N (%)** | **n/N (%)** | **n/N (%)** |
| **P-value** | **P-value** | **P-value** |
| **n/N (%)** | **n/N (%)** | **n/N (%)** |
| **P-value** | **P-value** | **P-value** |
| **n/N (%)** | **n/N (%)** | **n/N (%)** |
| **P-value** | **P-value** | **P-value** |
| **n/N (%)** | **n/N (%)** | **n/N (%)** |
| **P-value** | **P-value** | **P-value** |
| **n/N (%)** | **n/N (%)** | **n/N (%)** |
| **P-value** | **P-value** | **P-value** |
| **n/N (%)** | **n/N (%)** | **n/N (%)** |
| **P-value** | **P-value** | **P-value** |
| **n/N (%)** | **n/N (%)** | **n/N (%)** |
| **P-value** | **P-value** | **P-value** |
| **n/N (%)** | **n/N (%)** | **n/N (%)** |
| **P-value** | **P-value** | **P-value** |
| **n/N (%)** | **n/N (%)** | **n/N (%)** |
| **P-value** | **P-value** | **P-value** |
| **n/N (%)** | **n/N (%)** | **n/N (%)** |
| **P-value** | **P-value** | **P-value** |
Obese patients in our study showed a 45% increase in median time of SARS-CoV-2 shedding compared to their nonobese counterparts. However, obesity was not associated with prolonged duration of high viral load SARS-CoV-2 shedding. Recent studies indicate that obesity may be associated with prolonged SARS-CoV-2 shedding, in a similar manner to prolonged shedding seen in obese adults with influenza A virus [37, 38]. See Supplementary Material for further discussion.

Most participants developed anti-spike protein antibodies by day 14, with fewer immunocompromised PLHIV developing antibodies compared to HIV-uninfected persons. Overall, lower median anti-spike protein antibody titers were detected in PLHIV. Our study showed 14 individuals (4 HIV-uninfected

---

**Figure 3.** Kaplan-Meier plots of proportion of high viral load SARS-CoV-2 shedding by days following symptom onset by (A) HIV status and (B) HIV viral load in persons living with HIV. Abbreviations: HIV, human immunodeficiency virus; SARS-Cov-2, severe acute respiratory syndrome coronavirus 2.

**Figure 4.** Spike protein antibody binding by HIV status by day 7, 14 and 21, post symptom onset amongst hospitalized SARS-CoV-2-infected participants (n = 201). Abbreviations: HIV, human immunodeficiency virus; SARS-Cov-2, severe acute respiratory syndrome coronavirus 2.
persons and 10 PLHIV—8 of whom had low CD4 count) who did not develop antibodies within the initial 21 days’ follow-up period, half of whom showed prolonged shedding (including 5 PLHIV with CD4 count < 200 cells/µL). Other studies have found similar findings in immunocompromised individuals with prolonged viral shedding having negative seroconversion [15, 16].

The cohort of participants from 20 public hospitals is likely representative of the hospitalized COVID-19 South African adult population; however, the analysis did not account for within-hospital correlations due to case mix, treatment strategies, or interhospital differences in quality of care [39]. Thrice weekly collection of NP/OP swabs to detect ongoing SARS-CoV-2 viral shedding may result in underestimated viral shedding due to interval censoring of the data. A major limitation of our study is the use of qualitative Ct values as a proxy for viral load. Although all specimens were tested in the same laboratory, using standardized technique and assays, quantitative RT-PCR was not performed using calibration curves to determine viral load. In addition, we were unable to perform viral culture to confirm shedding of infectious virus at proxy Ct values < 30. Our findings may not be generalizable to outpatients with mild COVID-19, as hospitalized COVID-19 patients may represent more severe disease and therefore shed for a longer duration. Nonenrollment of participants due to unavailability of HIV test data (37% (702/1875) of nonenrollments) may have introduced bias due to potential differences in persons willing to undergo HIV testing versus those who are unwilling. Previous South African studies have shown similar unknown HIV results, as opt-out policies on HIV testing are not routinely followed [39]. Although sensitivity analyses in our study did not show much effect when excluding patients who died (data not shown), it should be noted that in-hospital mortality in our study was low (8%) compared to 23% in Jassat et al, as patients too ill to consent would have been excluded [39]. Follow-up of participants’ post-hospital discharge was challenging due to stigma of COVID-19 in the communities, safety concerns and travel limitations. Fifty-eight participants were lost to follow-up prior to cessation of shedding; however, the accelerated time failure Weibull regression analysis included patient data up until the patient was lost to follow-up, thereby utilizing all data generated.

Immunocompromised persons living with HIV shed SARS-CoV-2 at a higher viral load for a longer duration, and have lower anti-spike protein antibody levels than HIV-uninfected persons, which could lead to increased transmission and ongoing viral evolution of SARS-CoV-2, unless HIV control is achieved. During the COVID-19 pandemic, access to HIV testing and treatment with an aim for HIV viral suppression remains extremely important. In high HIV-prevalence settings better HIV control may potentially decrease the transmission period of SARS-CoV-2 in communities.

### Supplementary Data

Supplementary materials are available at *Clinical Infectious Diseases* online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyrighted and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Supplementary Figure 1: Mosaic of relative SARS-CoV-2 Ct-values of nasopharyngeal/oropharyngeal swabs taken every second day from persons living with HIV and HIV-uninfected persons who were hospitalized with COVID-19, South Africa, May through December 2020 (n = 257).

Supplementary Table 1: Reasons for non-enrolment by HIV status amongst persons screened for enrolment into the SARS-CoV-2 shedding study in South Africa

Supplementary Table 2: Accelerated Weibull Regression for duration of SARS-CoV-2 N gene detection by RT-PCR among hospitalized persons living with HIV, South Africa

Supplementary Table 3: Accelerated Weibull Regression for time taken from onset of symptoms to reach SARS-CoV-2 RT-PCR N gene Ct-value of > 30 among a subset of hospitalized persons living with HIV with laboratory confirmed SARS-CoV-2 infection and initial study SARS-CoV-2 RT-PCR N gene Ct-value of < 30, South Africa

Supplementary Table 4: Presence of SARS-CoV-2 virus in blood and stool among hospitalized persons with laboratory confirmed SARS-CoV-2 infection, South Africa

### Notes

**Acknowledgments.** The authors thank the participants in the study for their time and patience, as well as the GERMS-SA surveillance officers and team members of the Centre for Respiratory Diseases and Meningitis at the NICD.

Although not part of the COVID-19 Shedding Study Group, the following individuals assisted in the study:

- Livingstone Hospital: Vanessa Pearce, Microbiology, National Health Laboratory Service, Eastern Cape;
- Pelonomi Academic Hospital: Dewald Steyn, Internal Medicine, Pelonomi Hospital, Bloemfontein, Free State;
- Dr George Mukhari Academic Hospital: Temitayo Famoroti, Clinical Virology, National Health Laboratory Service, Gauteng; and
- Mdlink, Medicine, Dr George Mukhari Hospital, Gauteng; King Edward III Hospital: Prasha Mahabeer, Microbiology, National Health Laboratory Service, Kwazulu-Natal; Mankweng Hospital: Samuel Cana, Medicine, Mankweng Hospital, Limpopo.

- Members of the COVID-19 Shedding Study Group and their affiliations.

- Members from the various hospital sites that made up the COVID-19 Shedding Study Group.

- Dora Nginza Provincial and Livingstone Hospitals:

- Author contributions. Conception and design of study: All authors.
- Data collection and laboratory processing: S. M., T. J., J. N. B., A. B., J. K., M. M., M. McM., J. M., V. Q., S. W., M. d. P., NW, A. v. G., C. C.
- Analysis and interpretation: S. M., T. C. C., A. v. G., J. N. B., A. B., J. K., M. McM., J. M., V. Q., S, W.

- Drafting or critical review of the article: All authors.

- Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

- Financial support. The study was funded by the Wellcome Trust (grant number 221003/Z/20/Z) in collaboration with the Foreign, Commonwealth and Development Office, United Kingdom; the US Centers for Disease Control and Prevention (co-operative agreement number: 6 U01IP001048-04-02), as well as the National Institute for Communicable Diseases, a division of the National Health Laboratory Service, South Africa. The funding agencies had no role in the development of the study protocol, data collection, analysis and interpretation, writing of the report, or decision to submit.

- Potential conflicts of interest. S. M. reports a grant from Sanofi Pasteur for research outside the submitted work. A. v. G. reports grants from US CDC Atlanta and CDC SA, Wellcome Trust, Sanofi, and from South African MRC, EDCTP partnership, BMGF through ASLM and Africa
CDC, Fleming Fund Regional Africa WGS (SEQAFRICA) outside the submitted work. C. C. reports grants from Welcome Trust, SA Medical Research Council (SAMRC), and US CDC related to the submitted work and grant to institute for COVID-19 Research from Sanofi Pasteur outside the submitted work; participation on a Member Scientific Advisory Committee—BCHW: Burden of COVID-19 among health care workers, assessing infection, risk factors, vaccine effectiveness, working experiences and one-health implications: a mixed methodology, multisite international study, study is focused on COVID-19—no tuberculosis. H. D. has received speaker fees from SANOFI, unrelated to the study. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

John Black: Department of Medicine, Walter Sisulu University, Port Elizabeth, Eastern Cape.

Pelonomi Academic and Universitas Academic Hospitals.

Dominique Goodhals: Division of Virology, National Health Laboratory Service (NHLS)/ University of the Free State, Bloemfontein, Free State.

Bonnie Maloba: Microbiology, University of the Free State, Bloemfontein Free State.

Samantha Potgieter: Internal Medicine, Division Infectious Diseases, University of the Free State, Bloemfontein, Free State.

Charlotte Maxeke Johannesburg Academic Hospital:

Marianne Black: Department of Clinical Microbiology and Infectious Diseases, University of the Witwatersrand, Johannesburg, Gauteng Microbiology, NHLS, Johannesburg, Gauteng.

Vindana Chibhabha: Clinical Microbiology, NHLS, Johannesburg, Gauteng Clinical Microbiology and Infectious Diseases, University of the Witwatersrand, Johannesburg, Gauteng.

Nonhlanhla Mbenenge: Virology, NHLS, Johannesburg, Gauteng Virology, University of the Witwatersrand, Johannesburg Gauteng.

Trusha Nana: Microbiology, NHLS, Johannesburg, Gauteng Department of Clinical Microbiology and Infectious Diseases, University of the Witwatersrand, Johannesburg, Gauteng.

Sarah Stacey: Department of Internal Medicine, University of the Witwatersrand, Johannesburg, Gauteng Department of Internal Medicine, Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, Gauteng.

Florette Teurnicht: Virology, NHLS, Johannesburg, Gauteng.

Dr George Mukhari Academic Hospital.

Masego Moncho: Microbiology, NHLS, Pretoria, Gauteng Microbiology, Sefako Makgatho Health Sciences University, Pretoria, Gauteng.

Maphoshane Nchabeleng: Microbiology, NHLS, Pretoria, Gauteng Microbiology, Sefako Makgatho Health Sciences University, Pretoria, Gauteng.

Grace Shikwambane-Ntlemo: Microbiology, NHLS, Pretoria, Gauteng Microbiology, Sefako Makgatho Health Sciences University, Pretoria, Gauteng Helen Joseph Hospital.

Rispah Chomba: Clinical microbiology, NHLS, Johannesburg, Gauteng Department of clinical microbiology and infectious diseases, School of Pathology, University of the Witwatersrand, Johannesburg, Gauteng.

Jeremy Nel: Division of Infectious Diseases, Department of Medicine, University of the Witwatersrand, Johannesburg, Gauteng.

Steve Biko Academic Hospital.

Anwar Hoosen: Medical Microbiology, University of Pretoria, Pretoria, Gauteng Microbiology Laboratory, NHLS, Tshwane Academic Division, Pretoria, Gauteng.

Mohamed Said: Medical Microbiology, University of Pretoria, Pretoria, Gauteng Tshwane Academic Division, NHLS, Pretoria, Gauteng.

Addington Hospital.

Junaib Bayat: Medicine, Addington Hospital, Durban, KwaZulu Natal.

Lisha Sookan: Medical Microbiology, NHLS, Durban, KwaZulu Natal Medical Microbiology, University of KwaZulu Natal, Durban, KwaZulu Natal.

Khine Swe Han: Medical Microbiology, NHLS, Durban, KwaZulu Natal Edendale and Northdale Hospitals.

Surendra Sirkar: Department of Health, Northdale Hospital, Pietermaritzburg, KwaZulu Natal.

Greys Hospital.

Halima Dawood: Medicine, Greys hospital, Pietermaritzburg, KwaZulu Natal Caprisa, University of KwaZulu Natal, Durban, KwaZulu Natal.

Sumaya Hafejee: Medical Microbiology, NHLS, Pietermaritzburg, KwaZulu Natal Medical Microbiology, University of KwaZulu-Natal, Pietermaritzburg, KwaZulu Natal.

King Edward III Hospital.

Somasundram Pillay: Internal Medicine, University of KwaZulu-Natal, Durban, KwaZulu Natal Internal Medicine, King Edward VIII Hospital, Durban, KwaZulu Natal.

Praksha Ramjathian: Medical Microbiology, NHLS, Durban, KwaZulu Natal Medical Microbiology, University of KwaZulu Natal, Durban, KwaZulu Natal.

RK Khan Hospital.

Nomonde Mvelase: Medical Microbiology, NHLS, Durban, KwaZulu Natal Medical Microbiology, University of KwaZulu-Natal, Durban, KwaZulu Natal.

Javid Mulla: Medicine, RK Khan and King Edward III Hospitals, Durban, KwaZulu Natal.

Polokwane Provincial and Mankweng Hospitals.

Ruth Lekalakala-Mokaba: Pathology, University of Limpopo, Polokwane, Limpopo Medical Microbiology, NHLS, Polokwane, Limpopo.

Rob Ferreira Hospital.

Matama Madua: Medicine, Rob Ferreira Hospital, Nelspruit, Mpumalanga.

Sindle Ntuli: Medical Microbiology, NHLS, Nelspruit, Mpumalanga.

Ebrahim Variava: Medicine, Klerksdorp/Tshepong Hospital Complex, Klerksdorp, North West.

Mitchells Plain Hospital.

Thomas Crede: Medicine, Mitchells Plain Hospital, Cape Town, Western Cape Medicine, University of Cape Town, Cape Town, Western Cape.

Tygerberg Hospital.

Kessendri Reddy: Division of Medical Microbiology and Immunology, Department of Pathology, Stellenbosch University, Cape Town, Western Cape Medical Microbiology, NHLS, Tygerberg Hospital, Cape Town, Western Cape.

Janjie Taljaard: Division of Infectious Diseases, Department of Medicine, Tygerberg Hospital and Stellenbosch University, Cape Town, Western Cape.

Andrew Whitelaw: Division of Medical Microbiology and Immunology, Department of Pathology, Stellenbosch University, Cape Town, Western Cape Medical Microbiology, NHLS, Tygerberg Hospital, Cape Town, Western Cape.

References

1. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease 2019 (COVID-19). Nat Commun 2021; 12:1–6.

2. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection: a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 1751:1–14.

3. CDC. COVID-19 interim guidance on duration of isolation and precautions for adults with COVID-19. 2021: 1–9. Available at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html. Accessed 30 June 2021.

4. Cevik M, Tate M, Lloyd O, Mararolo AE, Schafer JS, Ho A. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe 2021; 2:e13–22.

5. Peiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361:1767–72.

6. Pitzer VE, Leung GM, Lipsitch M. Estimating variability in the transmission of severe acute respiratory syndrome to household contacts in Hong Kong, China. Am J Epidemiol 2007; 166:355–63.

7. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med 2020; 26:672–75.
8. Tong ZD, Tang A, Li KF, et al. Potential presymptomatic transmission of SARS-CoV-2. Zhejiang Province, China, 2020. Emerg Infect Dis 2020; 26:1052–4.
9. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-19. Nature 2020; 581:465–9.
10. Tom MR, Mina MJ. To interpret the SARS-CoV-2 test, consider the cycle threshold value. Clin Infect Dis 2020; 02115:1–3.
11. To KK-W, Tsang OT-Y, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020; 20:565–74.
12. Bullard J, Dust K, Funk D, et al. Predicting infectious severe acute respiratory syndrome coronavirus 2 from diagnostic samples. Clin Infect Dis 2020; 71:2663–6.
13. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study. BMJ 2020; 369:1–8.
14. Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. Clin Infect Dis 2020; 2019:1–8.
15. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med 2020; 383:2586–8.
16. Tsang NNY, So HC, Ng KY, et al. Long term SARS-CoV-2 infectfulness among three immunocompromised patients: from prolonged viral shedding to SARS-CoV-2 superinfection. J Infect Dis 2021; 223:1522–7.
17. Karim F, Moosa M, Gosnell B, et al. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection. medRxiv 2021:1–13.
18. Goubet AG, Dubuisson A, Gerard A, et al. Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis. Cell Death Differ 2021; 17:57.
19. Tsang NNY, So HC, Ng KY, Cowling BJ, Leung GM, Ip DKM. Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis. Lancet Infect Dis 2021; 21:1233–45.
20. Tsang NNY, So HC, Ip DKM. Is oropharyngeal sampling a reliable test to detect SARS-CoV-2? Authors’ reply. Lancet Infect Dis 2021; 21:1348–9.
21. Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill 2020; 25:1–5.
22. Public Health Ontario. Group TOC-19 TTT. Focus on: an overview of cycle threshold values and their role in SARS-CoV-2 real-time PCR test interpretation. 2020:1–14. Available at: https://github.com/UCSD-AI4H/COVID-CT. Accessed 30 June 2021.
23. Whibmer CK, Ayres F, Hermansus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med 2021; 27:622–5.
24. Hsieh CL, Goldsmith IA, Schaub JM, et al. Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. Science 2020; 369:1501–5.
25. World Health Organization. WHO case definitions of HIV. World Heal Organization 2007; 52:1–46.
26. Gilroy S, Bronze M, HIV infection and AIDS workup. 2020. Available at: https://emedicine.medscape.com/article/211316-workup#c8. Accessed 30 June 2021.
27. World Health Organization. Clinical management of COVID-19. Available at: https://www.who.int/publications-detail-clinical-management-of-covid-19. Accessed 20 January 2021.
28. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3) clinical review & education special communication | caring for the critically ill patient. JAMA 2016; 315:801–10.
29. Harris PA, Taylor R, Minar BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform 2019; 95:1–10.
30. Collett D. Modelling survival data in medical research. London: Chapman & Hall, 1993.
31. Von Mollendorf C, Hellerscece O, Valley-Omar Z, et al. Influenza viral shedding in a prospective cohort of HIV-infected and uninfected children and adults in 2 provinces of South Africa, 2012–2014. J Infect Dis 2018; 218:1228–37.
32. Weinstock DM, Gubareva LV, Zaccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med 2003; 348:867–8.
33. Ison MG, Gubareva LV, Atmar RL, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis 2006; 193:760–4.
34. McMinn P, Carrello A, Cole C, Baker D, Hampson A. Antigenic drift of influenza A (H3N2) virus in a persistently infected immunocompromised host is similar to that occurring in the community. Clin Infect Dis 1999; 29:456–8.
35. Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 2020; 383:2291–3.
36. Kelly H, Wilkinson E, Lessells RJ, et al. Sixteen novel lineages of SARS-CoV-2 in South Africa. Nat Med 2021; 27:440–6.
37. Moricomi D, Masi S, Rebelo E, et al. Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding. Obes Res Clin Pract 2020; 14:205–9.
38. Maier HE, Lopez R, Sanchez N, et al. Antigenic drift of influenza A virus shedding in adults. J Infect Dis 2018; 1378:218.
39. Jassat W, Cohen C, Tempia S, et al. Risk factors for COVID-19-related in-hospital mortality in a high HIV and tuberculosis prevalence setting in South Africa: a cohort study. Lancet HIV 2021; 8:e554–67.